| 2024-11-12 | -2.13 % |
|
| 2024-11-07 | +0.44 % |
|
| 2024-10-30 | +1.06 % |
|
| 2024-10-29 | -0.48 % |
|
| 2024-10-28 | +0.24 % |
|
| 2024-10-25 | -1.79 % |
|
| 2024-10-24 | -0.47 % |
|
| 2024-10-22 | +0.28 % |
|
| 2024-10-21 | -2.17 % |
|
| 2024-10-18 | -0.96 % |
|
| 2024-10-17 | -0.61 % |
|
| 2024-10-16 | -1 % |
|
| 2024-10-15 | +1.68 % |
|
| 2024-10-14 | -0.04 % |
|
| 2024-10-11 | +0.3 % |
|
| 2024-10-10 | -0.79 % |
|
| 2024-10-09 | +1.61 % |
|
| 2024-10-08 | -0.06 % |
|
| 2024-10-07 | -1.07 % |
|
| 2024-10-04 | -0.37 % |
|
| 2024-10-03 | -1.7 % |
|
| 2024-10-02 | -2.32 % |
|
| 2024-10-01 | +1.04 % |
|
| 2024-09-30 | -0.11 % |
|
| 2024-09-27 | +0.53 % |
|
| 2024-09-26 | -1.43 % |
|
| 2024-09-25 | -0.2 % |
|
| 2024-09-24 | -0.58 % |
|
| 2024-09-23 | -1.31 % |
|
| 2024-09-20 | -0.05 % |
|
| 2024-09-18 | +0.3 % |
|
| 2024-09-16 | +1.81 % |
|
| 2024-09-12 | +0.47 % |
|
| 2024-09-09 | -2.06 % |
|
| 2024-09-06 | -0.63 % |
|
| 2024-09-04 | -0.67 % |
|
| 2024-09-03 | -1.58 % |
|
| 2024-08-14 | -0.71 % |
|
| 2024-08-13 | +0.8 % |
|
| 2024-08-12 | -0.93 % |
|
| 2024-08-08 | +1.27 % |
|
| 2024-08-06 | -1.03 % |
|
| 2024-08-05 | -2.51 % |
|
| 2024-08-02 | +1.21 % |
|
| 2024-08-01 | +0.61 % |
|
| 2024-07-23 | -1.04 % |
|
| 2024-07-22 | -0.06 % |
|
| 2024-07-17 | +0.36 % |
|
| 2024-07-12 | -0.94 % |
|
| 2024-07-09 | +0.21 % |
|
| 2024-07-05 | +0.48 % |
|
| 2024-07-03 | -1.46 % |
|
| 2024-07-02 | -0.14 % |
|
| 2024-07-01 | +3.31 % |
- Merck & Co Inc. (MRK) stock increased by 3.31% after the company announced the mutual exercise of an option to convert their co-development and co-commercialization agreement for opevesostat into an exclusive global license for Merck, granting Merck global exclusive rights to develop and commercialize opevesostat and other products targeting CYP11A1, leading to the stock rise.
- Goldman Sachs initiated coverage on Verizon Communications (NYSE:VZ) stock, assigning a Buy rating and setting a price target at $50.00 due to Verizon's renewed momentum in wireless operations, deployment of fixed wireless, attractive financial strategy, and potential for growth, all contributing to a positive outlook.
- The article discusses how Orion Corporation upgraded its full-year outlook for 2024 due to converting a co-development agreement with MSD (Merck & Co., Inc.) into an exclusive global license, which led to a positive impact on net sales and operating profit, causing the stock to go up by 3.31%.
|
| 2024-06-28 | -4.64 % |
|
| 2024-06-24 | +1.71 % |
|
| 2024-06-20 | +1.31 % |
|
| 2024-06-18 | +0.38 % |
|
| 2024-06-17 | -1.53 % |
- The article discusses Merck & Co.'s (MRK) recent approval of their 21-valent Pneumococcal Conjugate Vaccine, CAPVAXIVE, by the FDA, highlighting its efficacy in addressing invasive pneumococcal disease. The stock of Merck & Co. (MRK) went down last night by -1.53%, and stock fluctuations like these can be influenced by various factors such as market conditions, economic news, company performance, regulatory developments, and investor sentiment.
- Summary: Merck & Co. (MRK) stock was down by -1.53% last night as the company announced FDA approval of KEYTRUDA in combination with chemotherapy for treating endometrial carcinoma, marking the 40th indication for KEYTRUDA in the US.
Reason for stock going down: The decrease in Merck & Co. (MRK) stock might be attributed to various factors such as market conditions, investor sentiment, general economic trends, and reactions to the latest news and events related to the company and its products, like the FDA approval of KEYTRUDA for endometrial carcinoma.
|
| 2024-06-14 | +0.09 % |
|
| 2024-06-13 | -0.64 % |
|
| 2024-06-12 | -0.98 % |
|
| 2024-06-06 | +0.83 % |
|
| 2024-06-05 | +0.57 % |
|
| 2024-06-04 | +0.23 % |
- The article discusses promising trial results from Pfizer, Moderna, and Merck & Co., which have shown significant advancements in cancer treatment and diagnostics, leading to an increase in Merck & Co.'s stock last night. Merck & Co. stock goes up as the company, along with Moderna, reported durable efficiency of their combined melanoma treatment involving an experimental mRNA vaccine and Merck's Keytruda, showcasing significant progress in cancer treatment and diagnostics.
- BMO Capital maintained an Outperform rating on Merck & Co. Inc. (MRK) with a price target of $148.00 following the company's recent investor event showcasing advancements in the oncology sector, particularly in developing treatments targeting KRAS G12C, TROP2 ADC, and DLL3 with T-cell engaging therapies, as well as expanding sacituzumab govitecan-hziy with nine late-phase studies, leading to increased investor confidence and a 0.23% rise in the stock price.
|
| 2024-06-03 | +2.29 % |
|
| 2024-05-31 | +0.81 % |
|
| 2024-05-30 | -1.09 % |
|
| 2024-05-29 | -0.15 % |
|
| 2024-05-28 | -2.63 % |
- The article discusses Merck & Co's (MRK) successful results in its phase 3 KEYNOTE-522 trial for Keytruda in treating early-stage triple-negative breast cancer, leading to an increase in stock price, with Keytruda showing consistent safety profile and achieving a significant overall survival benefit compared to chemotherapy alone. Despite this positive news, MRK stock went down -2.63% last night, which could be attributed to various factors such as profit-taking, market trends, or external economic conditions.
- The article discusses Merck & Co. (MRK) announcing a quarterly dividend and focuses on the company's purpose and activities. Merck & Co. (MRK) stock was down by -2.63% last night. The stock may have gone down due to various factors including general industry conditions, competition, economic factors, regulations, technological advances, patent protections, and market predictions as outlined in the forward-looking statement of the company.
- The article announces that Merck & Co. (MRK) declared a quarterly dividend of $0.77 per share for the third quarter of 2024, but the stock was down by -2.63% last night. The stock went down possibly due to general industry conditions and competition, economic factors, regulatory impact on the pharmaceutical industry, market forecasting challenges, and other risks and uncertainties mentioned in the company's forward-looking statements.
|
| 2024-05-24 | -1.22 % |
- The article discusses updates from the 2024 American Society of Clinical Oncology (ASCO) annual meeting, highlighting advancements in cancer treatment, focusing on companies like Oncolytics Biotech Inc., Merck & Co., Inc. (MRK), Roche Holding AG, Amgen Inc., and BioNTech SE, with Merck & Co., Inc. (MRK) revealing new data at the meeting demonstrating advancements in oncology treatment approaches across their portfolio. Merck & Co.(MRK) stock was down -1.22% possibly due to broader market conditions, sector news, or specific company factors.
|
| 2024-05-23 | -0.01 % |
|
| 2024-05-22 | +0.26 % |
|
| 2024-05-20 | -0.15 % |
|
